Carisma Therapeutics Inc. (CARM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Carisma Therapeutics Inc. (CARM) has a cash flow conversion efficiency ratio of -2.201x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.91 Million) by net assets ($-867.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Carisma Therapeutics Inc. liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Carisma Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Carisma Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Carisma Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Carisma Therapeutics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ordinary Fully Paid Deferred Settlement
AU:HRZDB
|
-0.180x |
|
KRUNGTHAI CARD FGN BA 1
F:KRTA
|
-0.012x |
|
PTT Global Chemical Public Company Limited
F:GCB
|
-0.057x |
|
Yeh-Chiang Technology
TWO:6124
|
-0.087x |
|
Sorted Group Holdings Plc
LSE:SORT
|
1.476x |
|
musicMagpie PLC
LSE:MMAG
|
0.302x |
|
Fibra Mty S.A.P.I. de C.V.
MX:FMTY14
|
0.045x |
|
SCG PACKAGING -FGN- BA 1
F:5Y7A
|
0.039x |
Annual Cash Flow Conversion Efficiency for Carisma Therapeutics Inc. (2011–2024)
The table below shows the annual cash flow conversion efficiency of Carisma Therapeutics Inc. from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see CARM company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-27.91 Million | $-59.92 Million | 2.147x | +170.17% |
| 2023-12-31 | $26.53 Million | $-81.18 Million | -3.060x | -5869.38% |
| 2022-12-31 | $-142.67 Million | $-7.57 Million | 0.053x | +124.39% |
| 2021-12-31 | $171.71 Million | $-37.33 Million | -0.217x | -107.43% |
| 2020-12-31 | $-9.23 Million | $-27.01 Million | 2.927x | +108.32% |
| 2019-12-31 | $-26.70 Million | $-37.52 Million | 1.405x | +372.12% |
| 2018-12-31 | $44.21 Million | $-22.83 Million | -0.516x | +47.58% |
| 2017-12-31 | $18.03 Million | $-17.77 Million | -0.985x | -1553.09% |
| 2016-12-31 | $38.68 Million | $2.62 Million | 0.068x | +103.72% |
| 2015-12-31 | $18.94 Million | $-34.53 Million | -1.823x | -129.03% |
| 2014-12-31 | $36.83 Million | $-29.31 Million | -0.796x | +86.16% |
| 2013-12-31 | $2.35 Million | $-13.49 Million | -5.752x | -72.90% |
| 2012-12-31 | $5.74 Million | $-19.09 Million | -3.327x | -104.50% |
| 2011-12-31 | $-147.00K | $-10.87 Million | 73.939x | -- |
About Carisma Therapeutics Inc.
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced… Read more